Key to individualized cancer therapy via gene silencing found
May 27th, 2010 - 4:47 pm ICT by ANILondon, May 27 (ANI): In a breakthrough research, scientists at the McGill University, Department of Biochemistry have discovered that a small segment of a protein that interacts with RNA can control the normal expression of genes - including those that are active in cancer.
The research has important immediate applications for laboratory research and is another step toward the kind of individualized cancer therapies researchers are pursuing vigorously around the world.
Human cells need to produce the correct proteins at the right time and in the appropriate quantities to stay healthy.
One of the key means by which cells achieve this control is by “RNA interference”, a form of gene silencing where small pieces of RNA, called micro RNAs, obstruct the production of specific proteins by interacting with their genetic code.
However, not any piece of RNA can do this.
Dr. Bhushan Nagar and graduate student Filipp Frank, in collaboration with Dr. Nahum Sonenberg at McGill’s new Life Sciences Complex, used structural biology to unravel how a small segment in the Argonaute proteins, the key molecules of RNA interference, can select the correct micro RNAs.
And the team has discovered that Argonaute proteins can potentially be exploited to enhance gene silencing.
“RNA interference could be used as a viable therapeutic approach for inhibiting specific genes that are aberrantly active in diseases such as cancer. We now have a handle on being able to rationally modify micro RNAs to make them more efficient and possibly into therapeutic drugs,” Nature quoted Nagar as saying.
While therapeutic applications are many years away, this new insight provides an avenue to specifically control the production of proteins, which in cancer cells for example, are abnormal.
“This is fantastic news. You’ve seen stories lately about how we may see the end of chemotherapy? Well, this is part of that path in developing genetically based therapies that can be tailored to individual patients’ particular illnesses. It’s a great step forward,” said Dr. David Thomas, Chair of McGill’s Department of Biochemistry.
The study was published by the prestigious journal Nature. (ANI)
- Now, prostate cancer can be inhibited without disturbing body processes - Aug 10, 2010
- 'Good cholesterol' nanoparticles may help fight cancer - Apr 02, 2011
- Key enzyme in melanoma cell development found - Jun 18, 2010
- New process to 'program' cancer cell death created - Sep 08, 2010
- Scientists discover cancer treatment in 'junk DNA' - Sep 29, 2010
- This is it - women's immunity gene! - Sep 28, 2011
- Autism effects may be reversible - Apr 24, 2010
- New discovery holds promise for liver cancer treatment - Mar 23, 2011
- Micro-RNA that regulates insulin in obesity identified - Apr 01, 2011
- Study examines gene that may hold key to reducing spread of oral cancer - Jul 24, 2010
- New discovery could shrink dengue-spreading mosquito population - Dec 03, 2010
- MicroRNAs could increase amputation risk in diabetics - Jan 13, 2011
- Protein that shuttles RNA into mitochrondria discovered - Aug 08, 2010
- Molecular pathway responsible for Parkinson's disease identified - Jul 29, 2010
- Interfering genes protect monkeys from lethal Ebola virus post-exposure - May 30, 2010
Tags: argonaute, bhushan, breakthrough research, cancer cells, cancer therapies, cancer therapy, department of biochemistry, fantastic news, filipp, genetic code, human cells, laboratory research, mcgill university department, nahum, research scientists, rna interference, structural biology, therapeutic applications, therapeutic approach, therapeutic drugs